AU2003301905A8 - Compositions and methods for treating acute myeloid leukemia - Google Patents

Compositions and methods for treating acute myeloid leukemia

Info

Publication number
AU2003301905A8
AU2003301905A8 AU2003301905A AU2003301905A AU2003301905A8 AU 2003301905 A8 AU2003301905 A8 AU 2003301905A8 AU 2003301905 A AU2003301905 A AU 2003301905A AU 2003301905 A AU2003301905 A AU 2003301905A AU 2003301905 A8 AU2003301905 A8 AU 2003301905A8
Authority
AU
Australia
Prior art keywords
compositions
methods
myeloid leukemia
acute myeloid
treating acute
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003301905A
Other versions
AU2003301905A1 (en
Inventor
Graham J Lieschke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research Ltd
Ludwig Institute for Cancer Research New York
Original Assignee
Ludwig Institute for Cancer Research Ltd
Ludwig Institute for Cancer Research New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute for Cancer Research Ltd, Ludwig Institute for Cancer Research New York filed Critical Ludwig Institute for Cancer Research Ltd
Publication of AU2003301905A1 publication Critical patent/AU2003301905A1/en
Publication of AU2003301905A8 publication Critical patent/AU2003301905A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003301905A 2002-11-06 2003-11-05 Compositions and methods for treating acute myeloid leukemia Abandoned AU2003301905A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42401702P 2002-11-06 2002-11-06
US60/424,017 2002-11-06
PCT/US2003/034893 WO2004043353A2 (en) 2002-11-06 2003-11-05 Compositions and methods for treating acute myeloid leukemia

Publications (2)

Publication Number Publication Date
AU2003301905A1 AU2003301905A1 (en) 2004-06-03
AU2003301905A8 true AU2003301905A8 (en) 2004-06-03

Family

ID=32312737

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003301905A Abandoned AU2003301905A1 (en) 2002-11-06 2003-11-05 Compositions and methods for treating acute myeloid leukemia

Country Status (2)

Country Link
AU (1) AU2003301905A1 (en)
WO (1) WO2004043353A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9962370B2 (en) 2013-03-15 2018-05-08 Ligand Pharmaceuticals Incorporated Methods of treatment associated with the granulocyte colony-stimulating factor receptor
WO2018102457A1 (en) * 2016-11-30 2018-06-07 Ray Partha S Diagnosis, prognosis and treatment of acute myeloid leukemia
EP3580236A4 (en) * 2017-02-07 2020-12-09 ME Therapeutics Inc. Anti-g-csf antibodies and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5902584A (en) * 1994-02-08 1999-05-11 Ludwig Institute For Cancer Research Antibodies which bind the G-CSF receptor extracelluar domain and methods of treatment
EP1019065A4 (en) * 1997-09-17 2002-02-20 Univ East Carolina Multiple target hybridizing nucleic acids, their preparation, compositions, formulation, kits and applications

Also Published As

Publication number Publication date
WO2004043353A3 (en) 2004-11-18
AU2003301905A1 (en) 2004-06-03
WO2004043353A2 (en) 2004-05-27

Similar Documents

Publication Publication Date Title
IL208191A0 (en) Compositions and methods for treating rage-associated disorders
IL176259A0 (en) Compositions and methods for treating diabetes
PT1578446E (en) Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same
EP1468118A4 (en) Methods and compositions for treating cancer
AU2003236527A8 (en) Compounds, compositions, and methods
AU2003265242A8 (en) Compounds, compositions, and methods
ZA200502843B (en) Methods and compositions for providing glutamine
GB0601708D0 (en) Compositions And Methods For Treating Gynaecological Disorders
EP1680535A4 (en) Electroplating compositions and methods for electroplating
EP1572118A4 (en) Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 216
AU2003256805A8 (en) Compounds compositions and methods
AU2003268032A8 (en) Composition and methods for treatment and screening
AU2003297573A8 (en) Compositions and methods for treating transplants
EP1395280A4 (en) Composition and methods for affecting metallocorrinoid uptake
EP1626711A4 (en) Compositions and methods for treating cancer
EP1389903A4 (en) Feed additive compositions and methods
EP1435979A4 (en) Methods for treating multiple sclerosis
AU2003267169A8 (en) Compounds, compositions and methods
AU2003301905A8 (en) Compositions and methods for treating acute myeloid leukemia
AU2003298708A8 (en) Gpc99 and gpc99a: methods and compositions for treating cancer
AU2003275433A8 (en) Compositions and methods for treating pain
EP1587405A4 (en) Novel compositions and methods for cancer
IL163878A0 (en) Compositions and methods for treating mdma-inducedtoxicity
AU2003295604A8 (en) Gpc15: methods and compositions for treating cancer
GB0223325D0 (en) Treating cancer

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase